Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
918.46B
Market cap918.46B
Price-Earnings ratio
35.53
Price-Earnings ratio35.53
Dividend yield
0.63%
Dividend yield0.63%
Average volume
4.03M
Average volume4.03M
High today
$977.50
High today$977.50
Low today
$975.25
Low today$975.25
Open price
$985.00
Open price$985.00
Volume
14.61K
Volume14.61K
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

Eli Lilly(LLY) stock is priced at $975.73, giving the company a market capitalization of 918.46B. It carries a P/E multiple of 35.53 and pays a dividend yield of 63.1%.

On 2026-05-08, Eli Lilly(LLY) stock traded between a low of $975.25 and a high of $977.50. Shares are currently priced at $975.73, which is +0.0% above the low and -0.2% below the high.

The Eli Lilly(LLY)'s current trading volume is 14.61K, compared to an average daily volume of 4.03M.

In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,133.95 and a 52-week low of $623.78.

In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,133.95 and a 52-week low of $623.78.

LLY News

Investor's Business Daily 21m
Eli Lilly's Retatrutide Is So Hot, The Unlaunched Weight-Loss Drug Is Already Getting Knocked Off

Technology Eli Lilly's Retatrutide Is So Hot, The Unlaunched Weight-Loss Drug Is Already Getting Knocked Off Licensing Eli Lilly's new weight-loss drug is creat...

Eli Lilly's Retatrutide Is So Hot, The Unlaunched Weight-Loss Drug Is Already Getting Knocked Off
TipRanks 46m
Eli Lilly price target raised to $1,235 from $1,183 at Guggenheim

Guggenheim analyst Seamus Fernandez raised the firm’s price target on Eli Lilly (LLY) to $1,235 from $1,183 and keeps a Buy rating on the shares. The firm updat...

TipRanks 10h
Major Legacy Investor Makes a Powerful Move in Eli Lilly Stock

New insider activity at Eli Lilly & Co ( (LLY) ) has taken place on May 7, 2026. Unlock hedge fund-level data and powerful investing tools for smarter, sharper...

Analyst ratings

85%

of 33 ratings
Buy
84.8%
Hold
12.1%
Sell
3%

More LLY News

TipRanks 13h
Eli Lilly Shareholders Back Board, Maintain Governance Structure - TipRanks

...

Eli Lilly Shareholders Back Board, Maintain Governance Structure - TipRanks
Investor's Business Daily 16h
How This Eli Lilly-Tied IPO Stock Fared In Its First Quarter

Retatrutide Black Market: Why Consumers Will Do Anything To Get Eli Lilly's New GLP 4:47 AM ET Eli Lilly's next-generation weight-loss drug, Retatrutide, could...

How This Eli Lilly-Tied IPO Stock Fared In Its First Quarter
Nasdaq 18h
Forget Eli Lilly: These 2 Stocks Have More Upside

Key Points Investors have placed a high valuation on Eli Lilly because they believe GLP-1 drugs represent a massive opportunity. Eli Lilly is growing quickly...

Forget Eli Lilly: These 2 Stocks Have More Upside
The Motley Fool 20h
Eli Lilly Now Has the World's Best-Selling Drug -- But Does That Make the Stock a No-Brainer Buy?

The success of Eli Lilly's (LLY 1.57%) diabetes treatment, Mounjaro, has now made it the top-selling drug on the planet, according to Bloomberg. And for investo...

Eli Lilly Now Has the World's Best-Selling Drug -- But Does That Make the Stock a No-Brainer Buy?
TipRanks 20h
Lilly and Regeneron Advance Obesity Combo Bet as Key Tirzepatide Trial Reaches Completion

Eli Lilly And Company (LLY), Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful in...

TipRanks 20h
Novo and Lilly Stocks Jump as Weight-Loss Pills Reveal Monster Market Potential

Shares of Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), two of the world’s largest drugmakers, rose slightly on Wednesday after data showed strong demand for th...

TipRanks 1d
Centessa Sets June Vote on $38-Per-Share Eli Lilly Takeover with Added CVR Upside

New activity is brewing for Centessa Pharmaceuticals ( (CNTA) ). The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vote. T...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.